台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效

國光生

(4142)
可現股當沖
  • 股價
    28.10
  • 漲跌
    ▼0.15
  • 漲幅
    -0.53%
  • 成交量
    739
  • 產業
    上市 生技醫療類股
  • 633人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
國光生 (4142)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/03/28     後一日»

券商獲利排行 - 2024/03/28

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  5.64%22.5022.51515026.626.6028.1
  5.40%18.70.218.51213126.626.626.828.1
  5.65%16.5016.51011026.626.626.828.1
  5.37%15.8015.81111026.726.7028.1
  5.94%15.8015.81010026.526.5028.1
  5.69%12.1012.188026.626.6028.1
  6.04%80855026.526.5028.1
  6.04%80855026.526.5028.1
  5.80%7.707.755026.626.6028.1
  5.68%7.607.655026.626.6028.1
  5.64%7.507.555026.626.6028.1
  5.64%7.507.555026.626.6028.1
  5.44%7.307.355026.726.7028.1
  5.36%7.207.255026.726.7028.1
  5.24%70755026.726.7028.1
  5.24%70755026.726.7028.1
  5.24%70755026.726.7028.1
  5.84%6.206.244026.626.6028.1
  5.64%60644026.626.6028.1
  5.44%5.805.844026.726.7028.1
  5.29%5.705.744026.726.7028.1
  5.05%5.405.444026.826.8028.1
  4.62%4.90.14.834126.526.526.628.1
  4.56%4.90.24.634126.626.626.828.1
  6.04%4.804.833026.526.5028.1
  6.04%4.804.833026.526.5028.1
  4.46%4.80.24.534126.626.626.828.1
  5.84%4.704.733026.626.6028.1
  5.71%4.604.633026.626.6028.1
  5.64%4.504.533026.626.6028.1
  5.64%4.504.533026.626.6028.1
  5.64%4.504.533026.626.6028.1
  5.51%4.404.433026.626.6028.1
  5.44%4.404.433026.726.7028.1
  5.24%4.204.233026.726.7028.1
  5.24%4.204.233026.726.7028.1
  0.68%4.2-1.85.94231926.626.626.528.1
  5.11%4.104.133026.726.7028.1
  4.85%3.903.933026.826.8028.1
  3.20%3.40.33.124226.626.626.728.1
  6.04%3.203.222026.526.5028.1
  6.04%3.203.222026.526.5028.1
  6.04%3.203.222026.526.5028.1
  6.03%3.203.212026.526.526.828.1
  3.89%3.103.123126.626.626.628.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.64%30322026.626.6028.1
  5.64%30322026.626.6028.1

券商虧損排行 - 2024/03/28

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -5.30%-70.60.3-70.8-4825026.626.526.628.1
  -5.02%-44.2-0.1-44.1-3123326.726.726.728.1
  -3.50%-32.6-0.9-31.7-21143526.626.726.628.1
  -5.86%-26.50-26.5-1701726.5026.528.1
  -5.38%-24.40-24.4-1601726.726.826.728.1
  -5.64%-16.50-16.5-1101126.6026.628.1
  -5.84%-15.50-15.5-1001026.6026.628.1
  -5.24%-140-14-1001026.7026.728.1
  -5.01%-13.3-0.5-12.8-821026.526.826.528.1
  -5.84%-12.40-12.4-80826.6026.628.1
  -5.81%-12.40-12.4-80826.6026.628.1
  -5.08%-9.5-0.2-9.3-61726.626.826.628.1
  -3.52%-9.40.4-9.8-731026.726.626.728.1
  -1.17%-8.4-3.6-4.8-2242726.626.626.528.1
  -6.04%-80-8-50526.5026.528.1
  -5.84%-7.80-7.8-50526.6026.628.1
  -5.44%-7.30-7.3-50526.7026.728.1
  -5.24%-70-7-50526.7026.728.1
  -5.24%-70-7-50526.7026.728.1
  -5.13%-6.90-6.9-50526.7026.728.1
  -5.84%-4.70-4.7-30326.6026.628.1
  -5.57%-4.50-4.5-30326.6026.628.1
  -5.24%-4.20-4.2-30326.7026.728.1
  -5.24%-4.20-4.2-30326.7026.728.1
  -5.24%-4.20-4.2-30326.7026.728.1
  -5.05%-4.10-4.1-30326.8026.828.1
  -6.04%-3.20-3.2-20226.5026.528.1
  -5.84%-3.10-3.1-20226.6026.628.1
  -5.64%-30-3-20226.6026.628.1
  -3.69%-3-0.1-2.9-21326.726.726.728.1
  -5.44%-2.90-2.9-20226.7026.728.1
  -5.34%-2.90-2.9-20226.7026.728.1
  -5.24%-2.80-2.8-10226.726.826.728.1
  -5.24%-2.80-2.8-20226.7026.728.1
  -5.24%-2.80-2.8-20226.7026.728.1
  -5.05%-2.70-2.7-20226.8026.828.1
  -5.05%-2.70-2.7-20226.8026.828.1
  -2.25%-1.8-0.3-1.5-12326.726.826.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.64%-1.50-1.5-10126.6026.628.1
  -5.64%-1.50-1.5-10126.6026.628.1
  -5.64%-1.50-1.5-10126.6026.628.1
  -5.64%-1.50-1.5-10126.6026.628.1
  -5.44%-1.50-1.5-10126.7026.728.1
  -5.44%-1.50-1.5-10126.7026.728.1
  -5.44%-1.50-1.5-10126.7026.728.1
  -2.64%-1.40.1-1.501226.626.526.628.1
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-2024/03/13
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章